Certara (CERT, Financial) has unveiled its new Non-Animal Navigator solution, aimed at aiding biopharmaceutical firms in transitioning from traditional animal testing methods. This innovation aligns with the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The roadmap is a significant development in drug research, offering an opportunity for companies to gain advantages such as expedited timelines and reduced costs by adopting alternative methods.
The Non-Animal Navigator leverages Certara’s in-depth experience with regulatory bodies like the FDA and EMA. It is designed to ensure that each client’s development programs are compliant with the latest standards and remain adaptable for future requirements. The solution provides strategic regulatory advice for developing preclinical programs that protect Investigational New Drug (IND) portfolios and incorporate New Approach Methodologies (NAMs), ensuring alignment with regulatory expectations.
Additionally, the solution offers an Integrated Preclinical Development Plan that synthesizes multiple data types, including in vitro and in vivo evidence, real-world data, and biosimulation results, with expert input on toxicology. To further enhance preclinical processes, the Non-Animal Navigator includes the Optimized AI-Enabled Modeling Toolkit. This toolkit, featuring the widely-used Simcyp Simulator(R) and ready-to-implement monoclonal antibody Quantitative Systems Pharmacology models, helps accelerate study timelines by utilizing advanced PBPK modeling platforms.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Certara Inc (CERT, Financial) is $13.89 with a high estimate of $16.00 and a low estimate of $11.00. The average target implies an upside of 7.58% from the current price of $12.91. More detailed estimate data can be found on the Certara Inc (CERT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Certara Inc's (CERT, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Certara Inc (CERT, Financial) in one year is $20.73, suggesting a upside of 60.57% from the current price of $12.91. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Certara Inc (CERT) Summary page.
